In combination with anti-PD-1/PD-L1 treatment, they can increase tumor-infiltrating CD8+ T cells and the CD8+/regulatory T cell ratio and decrease myeloid-derived suppressor cells (MDSCs) in the TME [37,38,39,40,41,42,43,44]. This evidence concerns the gene CD8A and neoplasm.